The possibility of the angiotensin-converting enzyme (fosinopril) application in patients with comorbid cardiorespiratory diseases

Cover Page

Cite item

Full Text

Abstract

This review notes the possibility of renin-angiotensin-aldosterone system (RAAS) blocking as a special therapeutic strategy in case of chronic obstructive pulmonary disease (COPD) and, in particular, the role of angiotensin-converting enzyme (ACE) inhibitors in the treatment of comorbid cardiovascular pathology associated with COPD. We know that the increased renin-angiotensin system activity can contribute to the pathogenesis and progression of COPD. The data show that ACE inhibitors application is associated with the reduction in mortality in elderly patients with COPD, hospitalized due to worsening. We have results showing beneficial skeletal muscles and cardiovascular morbidity effects of ACE inhibitors in patients with COPD.The review shows that ACE inhibitors, particularly fosinopril, remain their clinical relevance in treating patients with cardiorespiratory pathology. Fosinopril action is multiplex and is determined not only by the effect on blood pressure, left ventricular systolic and diastolic dysfunction (the cause of chronic heart failure), but also by the normalization of the RAAS functioning and organoprotective effect. Fosinopril is a drug with favorable metabolic profile and low incidence of adverse events.

About the authors

N. A Karoli

V.I.Razumovskii Saratov State Medical University of the Ministry of Health of the Russian Federation

д-р мед. наук, проф. каф. госпитальной терапии лечебного фак-та ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского 410012, Russian Federation, Saratov, ul. Bol'shaia Kazach'ia, d. 112

A. P Rebrov

V.I.Razumovskii Saratov State Medical University of the Ministry of Health of the Russian Federation

Email: andreyrebrov@yandex.ru
д-р мед. наук, проф., зав. каф. госпитальной терапии лечебного фак-та ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского 410012, Russian Federation, Saratov, ul. Bol'shaia Kazach'ia, d. 112

References

  1. Sin D.D, Anthonisen N.R, Soriano J.B, Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J 2006: 28; 1245-57.
  2. Lopez A.D, Shibuya K, Rao C et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397-412.
  3. Burt V.L, Cutler J.A, Higgins M et al. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension in the Adult US Population. Hypertension 1995; 26: 60-9.
  4. Chandy D, Aronow W.S, Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control 2013; 6: 101-9.
  5. Кароли Н.А., Ребров А.П. Артериальная гипертензия у пациентов с бронхиальной астмой и хронической обструктивной болезнью легких. Клиницист. 2011; 2: 20-30.
  6. Ольбинская Л.И., Белов А.А. Динамика суточного профиля артериального давления при хронических обструктивных заболеваниях легких в сочетании с артериальной гипертонией на фоне лечения эналаприлом. Тер. арх. 2002; 3: 59-62.
  7. Incalzi A.R, Fuso L, De Rosa M et al. Co - morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-800.
  8. Anthonisen N.R, Connet J.E, Enright P.L, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-9.
  9. Huiart L, Ernst P, Ranouli X, Suissa S. Low - dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-9.
  10. Кароли Н.А., Ребров А.П. Смертность при хронической обструктивной болезни легких: роль коморбидности. Клин. медицина. 2008; 3: 18-21.
  11. Almagro P, Calbo E, Echagilen A.O et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-8.
  12. Hansell A.L, Walk J.A, Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple case coding analysis. Eur Respir J 2003; 22: 809-14.
  13. Sin D.D, Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11.
  14. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
  15. Jessup M, Brozena S. Medical progress: heart failure. N Engl J Med 2003; 348: 2007-18.
  16. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013; 81: 1-94.
  17. Кароли Н.А., Ребров А.П. Хроническая обструктивная болезнь легких и кардиоваскулярная патология. Клиницист. 2007; 1: 13-9.
  18. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество, 2012.
  19. Бова А.А., Лапицкий Д.В. Современные подходы к диагностике и лечению ишемической болезни сердца у больных хронической обструктивной болезнью легких. Мед. новости. 2007; 9: 7-14.
  20. Стрюк Р.И. Эффективность и безопасность фозиноприла в клинической практике // Consilium Medicum. 2015; 17 (1): 18-21.
  21. Болотова Е.В., Дудникова А.В. Особенности факторов риска хронической болезни почек у пациентов с хронической обструктивной болезнью легких. Нефрология. 2015; 5: 28-33.
  22. Стаценко М.Е., Иванова Д.А., Спорова О.Е., Фабрицкая С.В. Особенности клиники, качества жизни и кардиоренальных взаимоотношений у пациентов с хронической сердечной недостаточностью и хронической обструктивной болезнью легких. Волгоградский науч.-мед. журн. 2012; 4 (36): 22-7.
  23. Shrikrishna D, Astin R, Kemp P.R, Hopkinson N.S. Renin - angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond) 2012; 123 (8): 487-98.
  24. Stockley R.A. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Curr Med Res Opin 2009; 25: 1235-45.
  25. Marshall R.P. The pulmonary renin - angiotensin system. Curr Pharm Des 2003; 9: 715-22.
  26. Hanif K, Bid H.K, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. Hypertens Res 2010; 33: 11-21.
  27. Kaparianos A, Argyropoulou E. Local renin - angiotensin II systems, angiotensin - converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem 2011; 18: 3506-15.
  28. Wong M.H, Chapin O.C, Johnson M.D. LPS-stimulated cytokine production in type I cells is modulated by the renin - angiotensin system. Am J Respir Cell Mol Biol 2011; 46: 641-50.
  29. Bradford C, Ely D, Raizada M. Targeting the vasoprotective axis of the renin - angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep 2010; 12: 212-9.
  30. Cuttica M.J, Kalhan R, Shlobin OA et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104: 1877-82.
  31. Ferreira A.J, Shenoy V, Yamazato Y et al. Evidence for angiotensin - converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 1048-54.
  32. Некрасов А.А., Кузнецов А.Н., Мельниченко О.В. Активация нейрогормональных систем как независимый механизм ремоделирования сердца у больных хронической обструктивной болезнью легких. Клин. медицина. 2014; 5: 50-4.
  33. Busquets X., Mac Farlane N.G, Heine-Suner D et al. Angiotensin - converting - enzyme gene polymorphisms, smoking and chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulm Dis 2007; 2: 329-34.
  34. Brice E.A, Friedlander W, Bateman E.D, Kirsch R.E. Serum angiotensin - converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 1995; 107: 706-10.
  35. Ucar G, Yildirim Z, Ataol E et al. Serum angiotensin converting enzyme activity in pulmonary diseases: correlation with lung function parameters. Life Sci 1997; 61: 1075-82.
  36. Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1235-8.
  37. Tkacova R, Joppa P. Angiotensin - converting enzyme genotype and C-reactive protein in patients with COPD. Eur Respir J 2007; 29: 816-7.
  38. Mortensen E.M, Copeland L.A, Pugh M.J.V et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
  39. Mancini G.B, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensin - converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47 (12): 2554-60.
  40. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 2003; 58: 629-31.
  41. Mortensen E.M, Copeland L.A, Pugh M.J et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
  42. Попова М.А., Терентьева Н.Н. Сравнительная эффективность ингибиторов ангиотензин - превращающего фермента спираприла, фозиноприла и эналаприла в комплексной терапии больных с сочетанием ишемической болезни сердца, хронических обструктивных болезней легких и артериальной гипертензии. Кардиоваск. терапия и профилактика. 2006; 3: 32-8.
  43. Хохлов А.Л., Воронина Е.А., Мельникова Ю.Е. Возможности применения ингибитора ангиотензинпревращающего фермента фозиноприла в клинической практике (обзор литературы) // Справочник поликлинического врача. 2014; 4: 35-9.

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies